Intellia Therapeutics
NTLA
136 hedge funds and large institutions have $589M invested in Intellia Therapeutics in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 50 increasing their positions, 34 reducing their positions, and 20 closing their positions.
152% more call options, than puts
Call options by funds: $2.57M | Put options by funds: $1.02M
47% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 34
5.31% more ownership
Funds ownership: 84.92% → 90.23% (+5.3%)
6% less funds holding
Funds holding: 144 → 136 (-8)
7% less capital invested
Capital invested by funds: $635M → $589M (-$46.6M)
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$80.1M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$33.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.28M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.63M |
| 5 |
BlackRock
New York
|
+$3.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$32.3M |
| 2 |
Millennium Management
New York
|
-$3.43M |
| 3 |
Renaissance Technologies
New York
|
-$2.69M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.79M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.52M |
NTLA Hedge Fund Activity: Q3 2019 in Review
136 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2019, worth a combined $589M — down 7.3% from $635M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of NTLA and 12 opened new positions — a net loss of 8 holders — while 34 trimmed existing stakes and 50 added.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $80.1M. The largest seller was Fidelity Investments, cutting an estimated $32.3M.
- 136 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2019, down from 144 in Q2 2019.
- Funds reported $589M of Intellia Therapeutics stock for Q3 2019, down 7.3% quarter-over-quarter.
- 12 funds opened new Intellia Therapeutics positions in Q3 2019 and 20 closed out, a net change of -8 holders.
- The largest Intellia Therapeutics buyer in Q3 2019 was Sumitomo Mitsui Trust Group, an estimated $80.1M added.
- The largest Intellia Therapeutics seller in Q3 2019 was Fidelity Investments, an estimated $32.3M sold.
Based on aggregated 13F filings for Q3 2019.